Privi Speciality Chemicals LtdQ2 FY25
Privi Speciality Chemicals Ltd Q2 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹3,607P/E: 36.9Market Cap: ₹12.1K CrSector: Chemicals & Petrochemicals
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
Yes
Order
Yes
Capex
Yes
3 of 5 growth signals are positive.
Full analysisRevenue guidance
Category 2- →The company targets a revenue of Rs. 5,000 crores and an EBITDA of around Rs. 1,000 crores within the next 3-4 years.
- →Annual growth guidance is about 20%, consistent with past performance.
- →Capacity expansions, including converting plants to continuous production and augmentation, are underway to support growth and meet demand.
- →Several new specialty aroma chemicals have been developed at lab and pilot levels, expected to drive future growth post the current capacity expansion slated for completion by March 2026.
- →The company aims to maintain EBITDA margins around 20-22% over the coming years.
- →Efforts are in progress to reduce net working capital days from about 140 to 120-125 to improve operational efficiency.
- →Overall, sustained strong demand, especially from FMCG sectors and stable contracted business (about 70%), supports optimistic growth prospects.
Margin guidance
Category 3- →The company targets sustained growth with a vision to achieve Rs. 5,000 crore revenue and Rs. 1,000 crore EBITDA in 3-4 years, implying ~20%+ EBITDA margins. (Page 12)
- →EBITDA margins have shown strength at ~22% currently and are expected to be sustainable going forward. (Page 15)
- →Capacity expansions and process debottlenecking are underway which will support continued volume and margin growth. (Pages 7, 14)
- →New specialty products from by-product streams and innovations at lab & pilot scale will drive future margin expansions and revenue growth. (Pages 13,14)
- →The firm expects gross margins (RMC costs) to stay stable at ~53-57%, with cost savings supporting EBITDA margin expansion. (Page 16)
- →Operational efficiencies like plant automation and continuous processing contribute positively to profitability. (Page 7)
- →The company aims to reduce net working capital days to 120-125 to improve cash flow. (Page 13)
- →Overall, management is confident of maintaining >20% EBITDA margins and 20%+ annual growth over next 3-5 years.
3 more insights locked — sign up free to unlock
Fundraise plans
Yes- →The company plans a significant CAPEX of about Rs. 1,100 crores over the next 2-3 years to support growth and capacity expansion.
- →Fundraising for this CAPEX will primarily be through a mix of internal accruals and bank debt.
- →Equity infusion is currently not favored due to its higher cost; hence, the company prefers debt and internal accruals.
- →There is no explicit mention of a new equity fundraising round in the near future.
- →The company aims to keep leverage at manageable levels and avoid becoming highly leveraged.
Order book
Yes- →The company has indicated that about 70% of their business for the financial year is already contracted.
- →There is strong ongoing demand for their products, which are essential FMCG items used daily (shower, washing clothes, brushing teeth).
- →They have a sustained demand outlook with no major customer delays expected in the near to medium term.
- →The company emphasizes a stable and positive growth trajectory based on current order backlog.
- →The products cater to large F&F industry customers (top 15 globally), facilitating easier commercialization of new products.
- →Capacity expansions and de-bottlenecking efforts are underway to meet growing demand, suggesting the order book is expected to be robust.
- →Orders are globally diversified, with about 70% exports.
- →No specific quantitative details on exact orderbook size were disclosed in the call.
Capex plans
Yes- →Total planned CAPEX to achieve the 5,000 crore revenue and 1,000 crore EBITDA vision is around Rs. 1,100 crores over the next few years.
- →The first phase of CAPEX is underway with about Rs. 280-300 crores invested, expected to complete by year-end, enabling 20% growth over the next couple of years.
- →Applications for environment clearances are in process for phases II and III to support further expansion.
- →Additional CAPEX includes Rs. 400 crores (approx.) planned for Privi Fine Sciences, with further investments expected mainly in the Lote plant.
- →Funding for CAPEX will be a mix of internal accruals and debt, with minimal reliance on equity.
- →Strategic focus on new and game-changing renewable route products supporting future growth and margin improvement.
How does Privi Speciality Chemicals Ltd rank vs peers in Chemicals & Petrochemicals?
Pro feature1Privi Speciality Chemicals Ltd
Rev 2Mar 3
See full Chemicals & Petrochemicals sector rankings
Want more stocks like Privi Speciality Chemicals Ltd?
Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.
Build my portfolio